Zenas BioPharma, Inc.
ZBIO Healthcare Biotechnology
Zenas BioPharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $10.0 million, up 100.0% from fiscal 2024. In the quarter to June 2026, EPS fell 41.6% and free cash flow fell 37.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow ZBIO
Zenas BioPharma, Inc. (ZBIO) Altman Z-score
Zenas BioPharma, Inc.'s Altman Z-score for fiscal 2025 is 1.73, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | 1.73 | 2.55 |
| FY2024 | −0.82 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.75 | — | 0.90 | |
| Retained earnings / total assets | (1.99) | — | −2.79 | |
| EBIT / total assets | (1.00) | — | −3.29 | |
| Market value of equity / total liabilities | 11.48 | — | 6.89 | |
| Sales / total assets | 0.03 | — | 0.03 | |
| Altman Z-score | Distress zone | 1.73 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −6.48 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| STOK Stoke Therapeutics, Inc. compare | 16.4× |
| OCUL Ocular Therapeutix, Inc. compare | 6.9× |
| NUVB Nuvation Bio Inc. compare | 3.6× |
| SEPN Septerna, Inc. compare | 3.4× |
| ZBIO Zenas BioPharma, Inc. | 1.7× |
| NTLA Intellia Therapeutics, Inc. compare | −1.9× |
| TRVI Trevi Therapeutics, Inc. compare | — |
| BHVN Biohaven Ltd. compare | — |
| GPCR Structure Therapeutics Inc. Sponsored ADR compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets